Genesys International Corporation Limited
Genesys International Corporation Limited Fundamental Analysis
Genesys International Corporation Limited (GENESYS.NS) shows moderate financial fundamentals with a PE ratio of 32.13, profit margin of 12.32%, and ROE of 6.79%. The company generates $3.2B in annual revenue with strong year-over-year growth of 56.89%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 62.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze GENESYS.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakGENESYS.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateGENESYS.NS shows balanced valuation metrics.
Growth Score
ModerateGENESYS.NS shows steady but slowing expansion.
Financial Health Score
ExcellentGENESYS.NS maintains a strong and stable balance sheet.
Profitability Score
WeakGENESYS.NS struggles to sustain strong margins.
Key Financial Metrics
Is GENESYS.NS Expensive or Cheap?
P/E Ratio
GENESYS.NS trades at 32.13 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, GENESYS.NS's PEG of -0.95 indicates potential undervaluation.
Price to Book
The market values Genesys International Corporation Limited at 1.84 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.77 times EBITDA. This is generally considered low.
How Well Does GENESYS.NS Make Money?
Net Profit Margin
For every $100 in sales, Genesys International Corporation Limited keeps $12.32 as profit after all expenses.
Operating Margin
Core operations generate 19.47 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.79 in profit for every $100 of shareholder equity.
ROA
Genesys International Corporation Limited generates $4.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genesys International Corporation Limited generates limited operating cash flow of $-339.91M, signaling weaker underlying cash strength.
Free Cash Flow
Genesys International Corporation Limited generates weak or negative free cash flow of $-26.52M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.63 in free cash annually.
FCF Yield
GENESYS.NS converts -0.21% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.13
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.95
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.84
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.96
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.21
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.86
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How GENESYS.NS Stacks Against Its Sector Peers
| Metric | GENESYS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.13 | 35.62 | Neutral |
| ROE | 6.79% | 1160.00% | Weak |
| Net Margin | 12.32% | -136515.00% (disorted) | Strong |
| Debt/Equity | 0.21 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 2.86 | 4.79 | Strong Liquidity |
| ROA | 4.26% | -311498.00% (disorted) | Weak |
GENESYS.NS outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genesys International Corporation Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
132.59%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
971.79%
Industry Style: Growth, Innovation, High Beta
High GrowthFCF CAGR
-255.23%
Industry Style: Growth, Innovation, High Beta
Declining